Imbruvica Demonstrates Long-Term Effectiveness and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia

Data presented at the European Hematology Society Congress showed that patients with chronic lymphocytic leukemia treated with Imbrica had significantly longer median progression-free survival compared to patients treated with chlorambucil.